Roche’s Perjeta shows benefits in treating aggressive breast cancer

Roche has announced new clinical trial data that demonstrates the benefits of its drug Perjeta in the treatment of certain forms of aggressive breast cancer.

In association with the Breast International Group, Breast European Adjuvant Study Team and Frontier Science Foundation, the company has reported positive findings from the phase III study APHINITY, showing that Perjeta met its primary endpoint in the trial.

Adjuvant treatment with a combination of Perjeta, Herceptin and chemotherapy was shown to deliver a statistically significant reduction in the risk of recurrence of invasive disease or death in people with HER2-positive early breast cancer compared to Herceptin and chemotherapy alone.

This means people with this aggressive type of early breast cancer were able to live longer without their disease returning, while the safety profile of the Perjeta-based regimen was consistent with previous studies.

Dr Sandra Horning, chief medical officer and head of global product development at Roche, said: "These results from the positive APHINITY study represent an important addition to the body of data for Perjeta in the treatment of people with HER2-positive early breast cancer."

The combination of Perjeta, Herceptin and chemotherapy is licenced as a neoadjuvant treatment for people with this form of cancer in more than 75 countries.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.